THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
2026 Annual Meeting Results; Class III Directors Elected
Financial Results, Other Events
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results
Investor Presentation
Larimar Therapeutics Enters Underwriting Agreement for 20M Shares
Larimar Therapeutics Enters Exchange Agreement for Preferred Stock
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report